Clinigen Group PLC
LSE:CLIN
Clinigen Group PLC
LSE:CLIN
Price:
925
GBX
Market Cap:
£1.2B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Clinigen Group PLC
LSE:CLIN
|
UK |
|
China Zenith Chemical Group Ltd
HKEX:362
|
HK |
|
Nifco Inc
TSE:7988
|
JP |
|
T
|
Terna Energy SA
ATHEX:TENERGY
|
GR |
|
Takeda Printing Co Ltd
TSE:7875
|
JP |
Balance Sheet
Balance Sheet Decomposition
Clinigen Group PLC
Clinigen Group PLC
Balance Sheet Decomposition is not available for
Clinigen Group PLC
Clinigen Group PLC
Balance Sheet
Clinigen Group PLC
Clinigen Group PLC
Currency: GBP
| Jun-2012 | Jun-2013 | Jun-2014 | Jun-2015 | Jun-2016 | Jun-2017 | Jun-2018 | Jun-2019 | Jun-2020 | Jun-2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
5
|
8
|
22
|
28
|
28
|
28
|
36
|
84
|
143
|
83
|
|
| Cash |
0
|
0
|
22
|
28
|
28
|
0
|
36
|
84
|
143
|
83
|
|
| Cash Equivalents |
5
|
8
|
0
|
0
|
0
|
28
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
15
|
15
|
0
|
0
|
0
|
0
|
81
|
80
|
109
|
135
|
|
| Accounts Receivables |
15
|
11
|
0
|
0
|
0
|
0
|
73
|
73
|
97
|
123
|
|
| Other Receivables |
0
|
4
|
0
|
0
|
0
|
0
|
8
|
7
|
12
|
13
|
|
| Inventory |
3
|
3
|
0
|
0
|
0
|
0
|
21
|
35
|
44
|
57
|
|
| Other Current Assets |
0
|
8
|
3
|
18
|
8
|
0
|
15
|
32
|
18
|
28
|
|
| Total Current Assets |
23
|
37
|
0
|
0
|
0
|
0
|
154
|
231
|
313
|
303
|
|
| PP&E Net |
0
|
1
|
0
|
0
|
0
|
0
|
7
|
14
|
34
|
33
|
|
| PP&E Gross |
0
|
1
|
0
|
0
|
0
|
0
|
7
|
14
|
34
|
33
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
1
|
2
|
0
|
3
|
5
|
7
|
14
|
|
| Intangible Assets |
0
|
30
|
0
|
0
|
0
|
0
|
219
|
429
|
404
|
348
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
7
|
7
|
0
|
1
|
|
| Other Long-Term Assets |
10
|
2
|
0
|
0
|
0
|
0
|
3
|
3
|
7
|
11
|
|
| Other Assets |
16
|
9
|
9
|
157
|
176
|
0
|
279
|
383
|
384
|
371
|
|
| Total Assets |
48
N/A
|
79
+63%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
667
N/A
|
1 066
+60%
|
1 142
+7%
|
1 066
-7%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
15
|
6
|
10
|
48
|
69
|
0
|
70
|
70
|
62
|
74
|
|
| Accrued Liabilities |
0
|
0
|
1
|
38
|
17
|
0
|
33
|
52
|
58
|
87
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
2
|
0
|
17
|
69
|
70
|
0
|
0
|
0
|
4
|
5
|
|
| Other Current Liabilities |
2
|
21
|
0
|
0
|
0
|
0
|
12
|
122
|
79
|
7
|
|
| Total Current Liabilities |
19
|
28
|
0
|
0
|
0
|
0
|
114
|
243
|
203
|
173
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
173
|
336
|
451
|
414
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
31
|
41
|
34
|
30
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
9
|
2
|
|
| Total Liabilities |
19
N/A
|
28
+50%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
318
N/A
|
628
+98%
|
696
+11%
|
619
-11%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
30
|
42
|
0
|
0
|
0
|
0
|
181
|
183
|
188
|
211
|
|
| Additional Paid In Capital |
0
|
9
|
0
|
0
|
0
|
0
|
161
|
240
|
240
|
240
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
7
|
15
|
18
|
5
|
|
| Total Equity |
30
N/A
|
51
+71%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
350
N/A
|
438
+25%
|
446
+2%
|
447
+0%
|
|
| Total Liabilities & Equity |
48
N/A
|
79
+63%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
667
N/A
|
1 066
+60%
|
1 142
+7%
|
1 066
-7%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
83
|
83
|
0
|
0
|
0
|
0
|
122
|
132
|
133
|
133
|
|
Switch to:
Switch to:
See Also
Discover More
